scholarly journals Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Open Medicine ◽  
2018 ◽  
Vol 13 (1) ◽  
pp. 487-492 ◽  
Author(s):  
Daniel Kotrych ◽  
Szymon Korecki ◽  
Paweł Ziętek ◽  
Bartosz Kruk ◽  
Agnieszka Kruk ◽  
...  
Keyword(s):  
Bone Substitute ◽  
Bone Tumors ◽  
Bone Cyst ◽  
Bone Diseases ◽  
Long Term Results ◽  
Reconstructive Procedures ◽  
Benign Bone Tumors ◽  
Significant Clinical Improvement ◽  
Tumor Like Lesions

AbstractBackground: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.

Novel Unidirectional Porous β-Tricalcium Phosphate Used as a Bone Substitute after Excision of Benign Bone Tumors of the Hand: A Case Series

2018 ◽  
Vol 23 (03) ◽  
pp. 424-429 ◽  
Author(s):  
Akira Ikumi ◽  
Toru Funayama ◽  
Toshinori Tsukanishi ◽  
Hiroshi Noguchi ◽  
Masashi Yamazaki
Keyword(s):  
Bone Formation ◽  
Tricalcium Phosphate ◽  
Bone Substitute ◽  
Bone Tumors ◽  
Animal Studies ◽  
Case Series ◽  
Clinical Results ◽  
Benign Bone Tumors ◽  
Tumors Of The Hand ◽  
Satisfactory Clinical Result

Unidirectional porous β-tricalcium phosphate (UDPTCP; Affinos®, Kuraray, Tokyo, Japan) has been in clinical use since 2015. Animal studies have confirmed the excellent potential of UDPTCP with regard to bone formation and material absorption. We present the first three clinical cases using UDPTCP as a bone substitute after curettage of benign bone tumors of the hand. All three patients were males, 29-, 30- and 81-years-old, two having a diagnosis of enchondroma and the other, a bone ganglion, with a pathological fracture identified in one case. Over a mean follow-up of 10 months, all patients achieved satisfactory clinical result, with no adverse events of UDPTCP noted. Radiographic evidence of good bone formation and material absorption was observable over the postoperative course. UDPTCP provided satisfactory clinical results, with good biocompatibility and fast resorption characteristics. Therefore, UDPTCP could provide a safe and reliable filling substitute for bone defects following curettage of small bone tumors.

Long-Term Results of Allograft Replacement in the Management of Bone Tumors

1996 ◽  
Vol 324 ◽  
pp. 86-97 ◽  
Author(s):  
Henry J. Mankin ◽  
Mark C. Gebhardt ◽  
L. Candace Jennings ◽  
Dempsey S. Springfield ◽  
William W. Tomford
Keyword(s):  
Bone Tumors ◽  
Long Term Results

scholarly journals Mitral valverepair: types of correction, immediateand long-term results

2008 ◽  
Vol 14 (1) ◽  
pp. 91-96
Author(s):  
N. Shikhverdiev ◽  
G. Khubulava ◽  
S. Marchenko ◽  
M. Askerov
Keyword(s):  
Mitral Valve ◽  
Valve Replacement ◽  
Mitral Valve Replacement ◽  
Mitral Valve Repair ◽  
Surgical Correction ◽  
Long Term Results ◽  
Valve Repair ◽  
Reconstructive Procedures ◽  
Valve Pathology

The types of surgical correction of the mitral valve pathology, hospital and long-term results were studied. The mitral valve repair being compared to the mitral valve replacement is procedure of choice as it provides stable results. In the study we demonstrate that the long-term results of reconstructive procedures on the mitral valve have advantages over mitral valve replacement in terms of survival, freedom from reoperation and tromboembolc complications.

Telomerase Activity in Benign Bone Tumors and Tumor-like Lesions

1999 ◽  
Vol 195 (11) ◽  
pp. 753-757 ◽  
Author(s):  
Akira Kido ◽  
Repine Schneider-Stock ◽  
Kathrin Hauptmann ◽  
Albert Roessner
Keyword(s):  
Bone Tumors ◽  
Telomerase Activity ◽  
Benign Bone Tumors ◽  
Tumor Like Lesions

scholarly journals Denosumab: A potential new treatment option for recurrent Aneurysmal Bone Cyst of the spine

SICOT-J ◽  
2019 ◽  
Vol 5 ◽  
pp. 10 ◽  
Author(s):  
Arvind G. Kulkarni ◽  
Ankit Patel
Keyword(s):  
Local Recurrence ◽  
Human Monoclonal Antibody ◽  
Bone Cyst ◽  
Surgical Excision ◽  
Long Term Results ◽  
Osteolytic Lesions ◽  
Short Period ◽  
New Treatment

ABCs are expansile osteolytic lesions typically containing blood-filled spaces separated by fibrous septae. Standard treatment includes surgical resection or curettage and packing; however, for some spinal lesions, the standard approach is not optimal. One therapeutic strategy is to treat spinal ABC with an agent that targets a pathway that is dysregulated in a disease with similar pathophysiology. Denosumab, a human monoclonal antibody to RANKL is effective in the treatment of GCT's. Spinal ABCs are a therapeutic challenge and local recurrence is a concern. We report a case of aggressive recurrent ABC of dorsal spine in a 14-year old female with progressive neurologic deficit who underwent surgical excision and decompression with a recurrence in a short period for which a decompression and fixation was done. She had a recurrence after an asymptomatic period of 6 months and neurologic worsening. Having ruled out use of embolization and radiotherapy, a remission was achieved by treatment with Denosumab using the regimen for GCTs for a duration of 6 months. Follow-up MRI and CT scans at 24 months following inception of Denosumab depicted complete resolution and no recurrence. We conclude that Denosumab can result in symptomatic and radiological improvement in the recurrent locally aggressive ABC and may be useful in selected cases. Long-term results are mandatory to confirm the efficacy of Denosumab and to evaluate local recurrence after stopping Denosumab.

Sign in / Sign up

Export Citation Format

Share Document